Philip Siberg
Chief Executive Officer
Year-End Report 2025 presentation
Philip Siberg, CEO of Senzime, will present the Year-end report for 2025 on February 18, 9:00 CET.
During the same day, there will also be Q&A with Redeye analyst Gustaf Meyer. The recording of the Q&A will be published later the same day at Redeye’s website
Presentation
Video will be available at this page February 18, 09:00 CET.
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Press release
Invitation to presentations of Senzime’s Q4 and Year-End Report 2025
Press release
Senzime secures major Ivy League US hospital system contract
Press release
Senzime’s Next-generation TetraGraph system receives regulatory approval in Japan
Financial info Jan - Sept 2025
Senzime Q3 2025: Strong growth and clear steps towards profitability
We continue to deliver strong growth, with sales year-to-date up 80 percent in constant currencies, corresponding to 70 percent in Swedish kronor. The growth is driven by an increasing number of hospital contracts and higher utilization among existing customers.
76
Net sales, MSEK
70
Net sales, % increase
62
Sales of disposable sensors, % increase
62.9
Gross margin before depreciation, %
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.